Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastric cancer associated transcript 1 (non-protein coding) (GACAT1)
- Target
- GACAT1
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
Gastric cancer associated transcript 1 (GACAT1) is a long non-coding RNA, also known as LINC00876, AC096655.1-002, and long intergenic non-protein coding RNA 876. It is abnormally expressed in gastric cancer tissues and regulates proliferation, migration, invasion, and resistance to chemotherapeutic agents such as doxorubicin and vincristine. Mechanistically, GACAT1 modulates cancer phenotypes by influencing the PTEN/AKT/mTOR/S6K1 signaling pathway, making it a candidate target for strategies seeking to overcome chemoresistance. GACAT1 is not a protein-coding gene or traditional receptor/enzyme but is considered part of the emerging class of non-coding RNA regulators relevant to oncogenesis and therapy resistance[1][2][3][5][6][7].
- Other names
- Long intergenic non-protein coding RNA 876LINC00876AC096655.1-002GACAT1 (non-protein coding)
02
Mechanism of action
Modulation of drug resistance via regulation of PTEN/AKT/mTOR/S6K1 signaling pathway. Indirect pathway: alteration of gene/protein expression that impacts cell survival and response to chemotherapy
03
Biological functions
Cell proliferationCell migrationCell invasionApoptosisRegulation of chemoresistance (notably doxorubicin and vincristine resistance)Regulation of gene transcription and signaling pathways (PTEN/AKT/mTOR/S6K1)
04
Disease associations
Cancer (gastric cancer: tumorigenesis, progression, and chemoresistance)
05
Safety considerations
Therapeutic manipulation of lncRNAs such as GACAT1 may pose risks of off-target gene regulatory effects, unintended impact on cell biology, and unpredictable toxicity seen with RNA-targeting therapeutics in oncology.
06
Interacting drugs
Doxorubicin
1 more in the full profile.
07
Biomarkers
GACAT1 expression level may serve as a biomarker for gastric cancer diagnosis, progression, and prediction of chemoresistance
Beyond the preview
Go deeper on Gastric cancer associated transcript 1 (non-protein coding) (GACAT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gastric cancer associated transcript 1 (non-protein coding) (GACAT1).